These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 28632421)

  • 1. Novel urushiol derivatives as HDAC8 inhibitors: rational design, virtual screening, molecular docking and molecular dynamics studies.
    Zhou H; Wang C; Deng T; Tao R; Li W
    J Biomol Struct Dyn; 2018 Jun; 36(8):1966-1978. PubMed ID: 28632421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, virtual screening, molecular docking and molecular dynamics studies of novel urushiol derivatives as potential HDAC2 selective inhibitors.
    Zhou H; Wang C; Ye J; Chen H; Tao R
    Gene; 2017 Dec; 637():63-71. PubMed ID: 28939339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the potential binding sites of some known HDAC inhibitors on some HDAC8 conformers by docking studies.
    Sixto-López Y; Gómez-Vidal JA; Correa-Basurto J
    Appl Biochem Biotechnol; 2014 Aug; 173(7):1907-26. PubMed ID: 24888409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxamates of para-aminobenzoic acid as selective inhibitors of HDAC8.
    Kulandaivelu U; Chilakamari LM; Jadav SS; Rao TR; Jayaveera KN; Shireesha B; Hauser AT; Senger J; Marek M; Romier C; Jung M; Jayaprakash V
    Bioorg Chem; 2014 Dec; 57():116-120. PubMed ID: 25462986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thermodynamics of binding of structurally similar ligands to histone deacetylase 8 sheds light on challenges in the rational design of potent and isozyme-selective inhibitors of the enzyme.
    Singh RK; Suzuki T; Mandal T; Balsubramanian N; Haldar M; Mueller DJ; Strode JA; Cook G; Mallik S; Srivastava DK
    Biochemistry; 2014 Dec; 53(48):7445-58. PubMed ID: 25407689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of Potent Panobinostat Histone Deacetylase Inhibitor Derivatives: Molecular Considerations for Enhanced Isozyme Selectivity between HDAC2 and HDAC8.
    Stoddard SV; May XA; Rivas F; Dodson K; Vijayan S; Adhika S; Parker K; Watkins DL
    Mol Inform; 2019 Mar; 38(3):e1800080. PubMed ID: 30369061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diarylcyclopropane hydroxamic acid inhibitors of histone deacetylase 4 designed by combinatorial approach and QM/MM calculations.
    Kollar J; Frecer V
    J Mol Graph Model; 2018 Oct; 85():97-110. PubMed ID: 30145395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An insight into selective and potent inhibition of histone deacetylase 8 through induced-fit docking, pharmacophore modeling and QSAR studies.
    Kashyap K; Kakkar R
    J Biomol Struct Dyn; 2020 Jan; 38(1):48-65. PubMed ID: 30633630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cyclodextrin-capped histone deacetylase inhibitor.
    Amin J; Puglisi A; Clarke J; Milton J; Wang M; Paranal RM; Bradner JE; Spencer J
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3346-8. PubMed ID: 23591111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rational design of selective HDAC2 inhibitors for liver cancer treatment: computational insights into the selectivity mechanism through molecular dynamics simulations and QM/MM calculations.
    Yang Y; Hu B; Yang Y; Gong K; Wang H; Guo Q; Tang X; Li Y; Wang J
    Phys Chem Chem Phys; 2021 Aug; 23(32):17576-17590. PubMed ID: 34369509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic structure-based pharmacophore model development: a new and effective addition in the histone deacetylase 8 (HDAC8) inhibitor discovery.
    Thangapandian S; John S; Lee Y; Kim S; Lee KW
    Int J Mol Sci; 2011; 12(12):9440-62. PubMed ID: 22272142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of novel potential selective HDAC8 inhibitors by combine ligand-based, structure-based virtual screening and in-vitro biological evaluation.
    Debnath S; Debnath T; Bhaumik S; Majumdar S; Kalle AM; Aparna V
    Sci Rep; 2019 Nov; 9(1):17174. PubMed ID: 31748509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantum polarized ligand docking investigation to understand the significance of protonation states in histone deacetylase inhibitors.
    Kalyaanamoorthy S; Chen YP
    J Mol Graph Model; 2013 Jul; 44():44-53. PubMed ID: 23732305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular dynamics study of HDAC8-largazole analogues co-crystals for designing potential anticancer compounds.
    Dewaker V; Srivastava PN; Verma S; Prabhakar YS
    J Biomol Struct Dyn; 2020 Mar; 38(4):1197-1213. PubMed ID: 30909817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of novel leads as potent inhibitors of HDAC3 using ligand-based pharmacophore modeling and MD simulation.
    Kumbhar N; Nimal S; Barale S; Kamble S; Bavi R; Sonawane K; Gacche R
    Sci Rep; 2022 Feb; 12(1):1712. PubMed ID: 35110603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docking of hydroxamic acids into HDAC1 and HDAC8: a rationalization of activity trends and selectivities.
    Ortore G; Di Colo F; Martinelli A
    J Chem Inf Model; 2009 Dec; 49(12):2774-85. PubMed ID: 19947584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent non-hydroxamate inhibitors of histone deacetylase-8: Role and scope of an isoindolin-2-yl linker with an α-amino amide as the zinc-binding unit.
    Greenwood SOR; Chan AWE; Hansen DF; Marson CM
    Bioorg Med Chem Lett; 2020 Mar; 30(5):126926. PubMed ID: 31952961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of the first histone deacetylase 6/8 dual inhibitors.
    Olson DE; Wagner FF; Kaya T; Gale JP; Aidoud N; Davoine EL; Lazzaro F; Weïwer M; Zhang YL; Holson EB
    J Med Chem; 2013 Jun; 56(11):4816-20. PubMed ID: 23672185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure of 'linkerless' hydroxamic acid inhibitor-HDAC8 complex confirms the formation of an isoform-specific subpocket.
    Tabackman AA; Frankson R; Marsan ES; Perry K; Cole KE
    J Struct Biol; 2016 Sep; 195(3):373-378. PubMed ID: 27374062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative study based on docking and molecular dynamics simulations over HDAC-tubulin dual inhibitors.
    Hassanzadeh M; Bagherzadeh K; Amanlou M
    J Mol Graph Model; 2016 Nov; 70():170-180. PubMed ID: 27750186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.